More than 11 years revealing secrets because there is no excuse for secrecy in God’s true religion – The Watchtower, June 1st 1997; Dan 2:47; Matt 10:26; Mark 4:22; Luke 12:2; Acts 4:19, 20.
Pharmaceutical biotechnology and pharmacovigilance (PV) are merging into a highly specialized field, driven by the unique safety profiles of biological drugs and the rapid integration of artificial intelligence (AI)
("pharmaceutical biotechnology" OR "biologic" OR "monoclonal antibody" OR "gene therapy") AND ("pharmacovigilance" OR "adverse event" OR "safety signal" OR "immunogenicity") AND ("case report" OR "cohort study" OR "meta-analysis") pharmaceutical biotechnology pv publication pdf
The backbone of pharmaceutical biotechnology lies in recombinant DNA (rDNA) technology. Before 1982, human insulin was extracted from pigs and cattle, leading to allergic reactions and supply issues. With rDNA, scientists inserted the human insulin gene into E. coli bacteria, turning them into microscopic factories. This breakthrough paved the way for other recombinant proteins, including human growth hormone (hGH), erythropoietin (EPO) for anemia, and clotting factors for hemophilia. coli bacteria, turning them into microscopic factories